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Maintenance of genome integrity via repair of DNA damage is a key biological process
required to suppress diseases, including Fanconi anemia (FA). We generated loss-of-function
human haploid cells for FA complementation group C (FANCC), a gene encoding a com-
ponent of the FA core complex, and used genome-wide CRISPR libraries as well as insertional
mutagenesis to identify synthetic viable (genetic suppressor) interactions for FA. Here we
show that loss of the BLM helicase complex suppresses FANCC phenotypes and we conﬁrm
this interaction in cells deﬁcient for FA complementation group I and D2 (FANCI and
FANCD2) that function as part of the FA I-D2 complex, indicating that this interaction is not
limited to the FA core complex, hence demonstrating that systematic genome-wide screening
approaches can be used to reveal genetic viable interactions for DNA repair defects.
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Maintaining genome integrity via repair of DNA damageis a key biological process required to suppress diseasesincluding cancer, ageing-related pathologies and dis-
eases associated with developmental defects and neurological
disorders1,2. Defects in DNA repair genes cause various rare
heritable diseases. One such disease is Fanconi anemia (FA) that
is caused by defects in FA genes and is characterized by bone
marrow failure, congenital defects, cancer predisposition and
chromosome fragility3. FA is believed to result from impaired
repair of DNA interstrand crosslink (ICL) damage, leading to
accumulation of DNA damage and genome instability. Further-
more, FA patients that develop cancer cannot be treated with
standard chemotherapy, including crosslinking agents, as they are
hypersensitive to such compounds.
Synthetic viability is the suppression of a genetic defect or
phenotype by mutation or abrogation of another gene or path-
way. Recently, haploid genetic screens have emerged as a pow-
erful method to perform suppression screens in human cells4–6.
Using near-haploid cell lines, such as HAP1, in combination with
a CRISPR-Cas9 inactivating library and insertional mutagenesis,
knock-outs for nearly all non-essential human genes can be
generated7,8.
Here, we introduce an approach for the systematic identiﬁca-
tion of synthetic viable interactions in human cells, illustrated
with FA defective cells. We identiﬁed synthetic viable interactions
for FA by performing genome-wide screens on isogenic human
haploid cells lacking the FA complementation group C (FANCC)
protein, following exposure to the DNA ICL-inducing agent
mitomycin C (MMC). We identify the BLM helicase complex as a
suppressor of Fanconi anemia phenotypes in human cells,
demonstrating that systematic screening approaches can be used
to reveal genetic viable interactions for DNA repair defects.
Results
Genome-wide screens identify synthetic viable interactions. To
validate the use of HAP1 as a cellular model system in which to
identify genetic synthetic viable interactions for genes associated
with DNA repair, we reproduced a reported synthetic viable
interaction that occurs between lamin A (mutated in the
premature-ageing disease Hutchinson-Gilford progeria syn-
drome) and the acetyl-transferase protein NAT109. Hence, we
utilized CRISPR-Cas9 lamin A mutant HAP1 cells (ΔLMNA)
(Supplementary Fig. 1a) which displayed a misshaped nuclear
morphology that could be corrected upon the addition of a
NAT10 inhibitor (Remodelin) (Supplementary Fig. 1b). Next, we
targeted FANCC in HAP1 cells using CRISPR-Cas9, generating a
frame-shift mutation (Supplementary Fig. 1c) and subsequently
the loss of FANCC protein expression (Supplementary Fig. 1d).
Resulting FANCC mutant cells (ΔFANCC) were hypersensitive to
MMC, both in a short-term dose-response assay (Supplementary
Fig. 1e) and in a long-term colony formation assay (Supple-
mentary Fig. 1f, g).
To identify synthetic viable interactions for FANCC, we set up
two genome-wide approaches to screen for mutations that
alleviate the hypersensitivity of ΔFANCC cells to MMC-induced
DNA damage (Fig. 1a). To this end, we exposed these cells to the
Genome-Scale CRISPR Knock-Out (GeCKO) library10 or inser-
tional mutagenesis8, the latter disrupting genes by random
insertion of a gene-trap cassette into the genome. Cells were
subsequently grown under MMC selection, leaving 5–10% of
ΔFANCC cells viable. Cells resistant to MMC were recovered and
subjected to next generation sequencing, to identify either the
enriched guide RNAs (gRNAs) or positions of insertional gene-
trap mutagenesis. Sequencing of the CRISPR library revealed a
sufﬁcient number of reads, covering each gRNA around 300 times
(Supplementary Fig. 2a, b). More than 99% of all gRNAs present
in the CRISPR library were detected (Supplementary Fig. 2c). Use
of insertional mutagenesis resulted in the targeting of >7000
genes with a total number of 22,772 unique insertions
(Supplementary Table 1). For both genome-wide screens, the
CRISPR-Cas9 mediated editing and insertional mutagenesis
screen, we used human haploid HAP1 cells since the likelihood
to receive loss-of-function mutations is increased by the fact that
only one genetic allele needs to be altered to yield a null
phenotype4,5,8,11. All experiments conﬁrming the results of the
genome-wide screens were performed using diploid HAP1 clones.
Encouragingly, both approaches led to the identiﬁcation of
NAD(P)H:quinone oxidoreductase1 (NQO1) as highly enriched
in ΔFANCC cells treated with MMC, compared to untreated wild-
type (WT) cells (Fig. 1b, c). NQO1 functions as a positive control,
since it is known that loss of NQO1 renders cells less sensitive to
MMC due to its functions as one of several bioreductases,
converting MMC from a pro-drug to an active form that can lead
to ICLs12. Moreover, NQO1 is found to carry loss-of-function
mutations in cancers that are MMC resistant13. Using the
CRISPR library, as well as insertional mutagenesis, we identiﬁed
the enrichment of several NQO1 gRNAs and multiple NQO1
inactivating insertions, respectively (Supplementary Fig. 3a, b).
To validate this genetic interaction, we designed gRNAs to target
NQO1 with Cas9 nickase14 (Supplementary Fig. 3c) and
conﬁrmed that editing resulted in a pool of frame-shift mutations
by immunoblotting (Supplementary Fig. 3d). Both WT and
ΔFANCC cells targeted for NQO1 (‘WT+NQO1 gRNA’ and
‘ΔFANCC +NQO1 gRNA’, respectively) displayed reduced MMC
toxicity in both a short-term dose-response assay (Supplementary
Fig. 3e) and a long-term colony formation assay (Supplementary
Fig. 3f, g).
Loss of BLM complex rescues sensitivity of FA cells to ICLs. We
identiﬁed several members of the BLM complex, using both
genome-wide CRISPR libraries (where we identiﬁed all four
complex members: BLM, RMI1, RMI2 and TOP3A) and inser-
tional mutagenesis (where we identiﬁed BLM and RMI1) (Fig. 1b,
c), and followed up on this ﬁnding. The BLM complex forms part
of a multienzyme DNA helicase and includes DNA Topoisome-
rase III Alpha (TOP3A), RMI1, RMI2, and the BLM helicase. The
BLM complex is bridged to the FA complex via FANCM15, and
indeed gRNAs targeting FANCM were also enriched using the
CRISPR library (Fig. 1b and Supplementary Fig. 4a). The BLM
complex functions in the resolution of DNA structures that arise
during the process of homologous recombination (HR) repair16.
By comparing enriched genes in the CRISPR screen performed on
MMC-treated ΔFANCC cells to enriched genes identiﬁed by an
additional CRISPR screen performed on MMC-treated WT cells,
we found that loss of the BLM complex speciﬁcally rescued
ΔFANCC but had little or no effect in WT cells (Supplementary
Fig. 4a). This indicates that the observed phenotype of increased
resistance upon loss of BLM is speciﬁc to FANCC deﬁcient cells
and most likely does not result from general pro-survival effects
due to diminished MMC uptake, impaired apoptotic signaling or
perturbed MMC activation. All six gRNAs for BLM and RMI1
were enriched in the CRISPR screen (Supplementary Fig. 4b). In
addition, inactivating insertion sites within BLM and RMI1 in the
gene-trap screen were identiﬁed (Supplementary Fig. 4c).
To validate the above ﬁndings, we generated BLM, RMI1 or
FANCM deﬁcient cells both in a WT background and in a
ΔFANCC background. Single and double knock-out clones were
conﬁrmed by Sanger sequencing (Supplementary Fig. 4d) and
immunoblotting (Supplementary Fig. 4e). Thus we conﬁrmed
that while loss of RMI1, BLM or FANCM in a WT background
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(ΔRMI1, ΔBLM, and ΔFANCM, respectively) had little effect on
MMC sensitivity, loss of one of these three factors in a FANCC-
deﬁcient background (ΔFANCCΔBLM, ΔFANCCΔRMI1, and
ΔFANCCΔFANCM) resulted in enhanced MMC resistance
(Fig. 1d–f). In support of our ﬁndings, it has been reported that
disruption of FANCM (Protein Hef ortholog) in a FANCC-
deﬁcient background in chicken DT40 cells suppresses cellular
sensitivity to cisplatin17. In addition, it has been shown that
mouse embryonic ﬁbroblasts lacking both FANCB (another
member of the FA core complex) and BLM are less sensitive to
MMC than FANCB single mutants18. However, intriguingly
chicken DT40 cells lacking both FANCC and BLM are not
noticeably less sensitive than FANCC single mutants19 and this
discrepancy may be due to species variation.
Since FANCC is part of the FA core complex, we next
investigated whether loss of BLM or RMI1 could rescue
cells lacking FANCI and FANCD2, that make up the FA I-D2
complex and function downstream of the FA core complex. To
this end, we generated FANCI and FANCD2 mutant
HAP1 cells (ΔFANCI and ΔFANCD2), as well as ΔFANCIΔRMI1
and ΔFANCD2ΔBLM double-deﬁcient cells (Supplementary
Fig. 4f, g). We observed that loss of RMI1 or BLM could rescue
the MMC hypersensitivity of FANCI and FANCD2 deﬁcient cells,
but did not enhance MMC resistance in WT cells (Fig. 1g, h),
indicating that this synthetic viable (genetic suppression)
interaction is not limited to FA core complex components.
To investigate whether the observed genetic interaction
between FA and the BLM complex was speciﬁc to MMC, we
treated cells with two additional crosslinking agents, cisplatin and
1,2,3,4-diepoxybutane (DEB) (Fig. 2a, b). In addition, we treated
cells with acetaldehyde, which is considered to be an endogenous
source of crosslinking damage in FA cells20–22 (Fig. 2c). We noted
that loss of BLM alleviated the cellular hypersensitivity of
ΔFANCC cells to all of these crosslinking agents.
p53 is partially functional in HAP1 cells. Because DNA-damage
induced cell death of FA cells has been shown to occur in a p53
dependent manner23, and since we did not retrieve TP53 or its
effectors in either of the genome-wide loss-of-function screens,
we next investigated the functionality of p53 in HAP1 cells.
Sequencing of TP53 conﬁrmed a previously reported point
mutation24,25 (Supplementary Fig. 5a). To test whether this
mutation impacted on cell survival of FA cells following exposure
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Fig. 1 Genome-wide CRISPR-Cas9 and insertional mutagenesis screens identify the BLM complex as a synthetic viable interaction for FANCC. a Workﬂow
for the identiﬁcation of genetic synthetic viable interactions for ΔFANCC cells following MMC exposure by two parallel genome-wide approaches: CRISPR-
Cas9 and insertional mutagenesis. b Viability-inducing genes identiﬁed using a genome scale CRISPR knock-out (GeCKO) library in ΔFANCC cells treated
with MMC, compared to untreated WT cells are shown in red, and include members of the BLM complex, FANCM and NQO1. Each dot represents the
average score of the six guide RNAs (gRNAs) per gene. c Viability-inducing genes identiﬁed using gene-trap insertional mutagenesis in ΔFANCC cells
treated with MMC, compared to untreated WT cells. Members of the BLM complex and NQO1 are labeled. For robust identiﬁcation of enriched genes in b,
c, hit selection was performed in two steps. First, each data set was partitioned into two groups, deﬁning the hit-group as data points with p< 0.001 and
fold-change >21.5. In a second step, hit selection was optimized using linear discriminant function analysis. d–h Indicated cell lines were exposed to MMC
for 4 days and cellular survival was assessed by CellTiter-Glo. Means and S.E.M. of biological triplicates are plotted
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to MMC, we generated HAP1 cells lacking p53 (ΔTP53) as well as
cells lacking both FANCC and p53 (ΔFANCCΔTP53) (Supple-
mentary Fig. 5b, c). Next, we treated these cells with MMC in
both short-term and long-term dose-response assays (Supple-
mentary Fig. 5d–f). We noted that loss of p53 only slightly
increased the resistance of ΔFANCC cells to MMC (Supple-
mentary Fig. 5d–f). This led us to address p53 functionality in
HAP1 cells. Thus, we treated human A549 cells (a TP53 WT cell
line) and HAP1 cells with Nutlin-3a, an MDM2 inhibitor. This
enhanced p53 stability in A549 cells and ensuing induction of the
p21 protein (Supplementary Fig. 5g). While we did observe low
levels of p21 protein in HAP1 cells, this was not increased upon
Nutlin-3a treatment, nor did Nutlin-3a increase p53 protein levels
in such cells. Next, we tested whether Nutlin-3a treatment could
sensitize HAP1 cells in both short-term and long-term dose-
response assays (Supplementary Fig. 5h–j). We did not observe an
increased sensitization to Nutlin-3a, which taken together with
our other data, these ﬁndings indicate that p53 is only partially
functional in HAP1 cells.
Loss of BLM reduces DNA damage and apoptosis of FA cells.
To probe the molecular mechanism of the observed suppression,
we measured generation and clearance of DNA damage using
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Fig. 2 Loss of the BLM complex in FANCC deﬁcient cells alleviates DNA damage and apoptosis induced by ICLs. a–c Treatment of indicated cell lines with
cisplatin, diepoxybutane (DEB) and acetaldehyde for 4 days. Survival assessed by CellTiter-Glo. d Indicated cells were left untreated (UT) or treated with
MMC for 24, 48, or 72 h, stained for γH2AX and analyzed by High Content Imaging. p-values determined by two-way ANOVA. e Cells were either left
untreated or treated with MMC for 24, 48, and 72 h, then apoptosis was measurement using propidium iodide (PE) Annexin V staining, followed by ﬂow
cytometry analysis. f Quantiﬁcation of chromosome breaks and gaps of 40 cells per cell line treated with MMC for 24 h followed by analysis of metaphase
spreads. p-value determined by Mann–Whitney U test. g Survival of indicated cells treated with either the PARP inhibitor olaparib (PARPi) or DMSO for
4 h, followed by MMC exposure for 4 days. Survival assessed by CellTiter-Glo. For all panels, means and S.E.M. of biological triplicates are plotted. ns= p>
0.05; *=p< 0.05; **=p< 0.01; ***=p< 0.001; ****=p< 0.0001
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Ser-139 phosphorylated histone H2AX (γH2AX) as a marker
(Fig. 2d). This analysis indicated a reduction in DNA damage at
later time points (48 and 72 h) in ΔFANCCΔBLM cells compared
to ΔFANCC cells which correlated with reduced levels of apop-
tosis (Fig. 2e and Supplementary Table 2). Next, we measured the
impact of loss of BLM in ΔFANCC cells on chromosomal
instability by assessing chromosomal aberrations (Fig. 2f). This
indicated that shortly after ICL induction (24 h after MMC
treatment), the number of chromosomal breaks and gaps in
ΔFANCCΔBLM cells were not signiﬁcantly altered, compared to
ΔFANCC.
Loss of BLM does not rescue general HR defects. DNA double-
strand breaks are generated as an intermediate structure during
ICL repair and are repaired through HR26. To test whether loss of
BLM can rescue the DNA-damage hypersensitivity of cells
defective in other HR proteins, we tested whether effects resulting
from depletion of BRCA1 could be compensated for by loss of
BLM. Hence, we depleted BRCA1 in WT and ΔFANCC cells,
then exposed them to MMC (Supplementary Fig. 6a–c). These
data indicated that loss of BLM did not alleviate the sensitivity of
BRCA1 depleted cells to MMC, indicating that this genetic
interaction with BLM is speciﬁc to the FA pathway.
MUS81 loss does not sensitize ΔFANCCΔBLM cells to MMC.
The BLM complex, also known as ‘dissolvasome’, can dissolve
catenated DNA structures that arise during replication and HR
repair27. The helicase activity of BLM in combination with the
topoisomerase activity of TOP3A are required to dissolve the
double Holliday junction that is formed during HR in a way that
results in a non-crossover DNA product and prevents sister
chromatid exchanges. Alternatively, the same structure can be
resolved by structure-speciﬁc nucleases such as MUS81-EME1 or
GEN1 that cut the DNA leading to crossover DNA products28. A
possible hypothesis for the observed suppression of FA DNA-
damage sensitivity by loss of BLM components is that in the
absence of a functional FA pathway, inappropriate or incomplete
processing of ICLs might result in a structure that cannot be
efﬁciently dissolved by the helicase activity of BLM, resulting in a
toxic intermediate. In the absence of the BLM complex, however,
preferential resolution by structure-speciﬁc nucleases, such as
MUS81-EME1, might be more efﬁcient and promote survival. A
recent study showed that BLM might contribute to the generation
of chromosome breaks and radials in a FANCB deﬁcient back-
ground, supporting this hypothesis29. A corollary of the above
model is that loss of MUS81-EME1 function would re-sensitize
ΔFANCCΔBLM cells to DNA-damaging agents. However, when
we tested this idea by depleting MUS81 using two independent
shRNAs in ΔFANCCΔBLM cells (ΔFANCCΔBLM shMUS81#1
and ΔFANCCΔBLM shMUS81#2) (Supplementary Fig. 6d), we
found that ΔFANCCΔBLM cells depleted for MUS81 were not
re-sensitized to MMC (Supplementary Fig. 6e). Thus we conclude
that MUS81 appears not to be used as an alternative nuclease to
BLM in the context of our analyses.
PARP inhibition re-sensitizes ΔFANCCΔBLM cells to MMC.
Recently, a role for alternative end joining in the FA pathway has
been reported30,31. As BLM may function in regulating the
pathway choice for DNA double-strand break repair, by pre-
venting alternative end-joining32, we asked whether its absence
could allow for the use of this pathway in the removal of ICLs in
FA-deﬁcient cells. As alternative end-joining is known to depend
on PARP, we inhibited PARP with a small molecule inhibitor
olaparib, and tested cellular survival to MMC. This led to a partial
sensitization of ΔFANCCΔBLM cells, thereby suggesting that
alternative end-joining may enhance survival of FA cells in the
absence of BLM function by repairing some DNA lesions (Fig. 2g
and Supplementary Fig. 6f).
Discussion
Although the exact mechanisms by which the BLM complex
impacts on the FA pathway still needs to be resolved, several
levels of crosstalk have been described. Apart from its role in the
resolution of HR intermediates, the BLM complex also plays an
early role in replication fork protection and remodeling during
ICL repair, since it is recruited to the site of the lesion upon
recognition by FANCM15,33. BLM recruitment and helicase
activity is important for proper downstream activation of the FA
pathway15, while FANCD2 is required for the maintenance of
BLM protein stability, for mediating phosphorylation of the BLM
complex members in response to DNA damage and to cooperate
with BLM to promote restart of stalled replication forks while
suppressing ﬁring of new replication origins34. It is thus evident
that coordinated action of BLM and FA proteins is necessary for
efﬁcient processing and repair of ICLs. Here we report that when
members of both complexes are absent, ICL lesions can be
channeled through alternative repair pathways, at the cost of
genome integrity.
BLM has also been shown to prevent CtIP- and Mre11-
mediated alternative non-homologous end-joining32, a repair
pathway that results in DNA sequence alterations and has also
been shown to be involved in ICL repair31. Thus, loss of BLM
might relieve suppression of alternative end-joining and promote
repair of the lesions in an error-prone manner, a hypothesis
supported by our data showing reduced γH2AX foci upon
treatment with MMC, without decreasing chromosomal aberra-
tions. This is supported by the partial sensitization of
ΔFANCCΔBLM cells to MMC upon inhibition of PARP.
In conclusion, through the use of parallel genome-wide
screens, we have shown that synthetic viable (genetic suppres-
sion) interactions for Fanconi anemia can be systematically
identiﬁed in human cells. We discovered that loss of the BLM
complex rescues survival of Fanconi anemia deﬁcient cells upon
generation of DNA damage by reagents that generate ICLs.
Methods
Cell lines and culture conditions. HAP1 cells were grown in Iscove’s Modiﬁed
Dulbecco’s Medium (IMDM) from GIBCO®, containing L-Glutamine and 25 mM
HEPES and supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/
Streptomycin (P/S). HEK293T cells for virus production were expanded in Dul-
becco’s Modiﬁed Eagle Medium (DMEM) from GIBCO, supplemented with 10%
FBS. A549 cells were grown in DMEM supplemented with 10% FBS and 1% P/S.
All cells were grown at 37 °C in a 3% oxygen and 5% CO2 atmosphere. Diploid
HAP1 clones used for all experiments (except the genome-wide screens) were
obtained by serial dilution of mixed populations of cells (consisting of both haploid
and diploid cells), followed by conﬁrmation of the ploidy status by FACS. All cell
lines used in this publication were tested negative for mycoplasma contamination
using the MycoAlert™ Mycoplasma Detection Kit.
Gene editing. Guide RNA pair design and cloning: For the generation of NQO1-
CRISPR knock-out cells, the Cas9 double-nickase system was used14. By combining
the CRISPR Design Tool (http://crispr.mit.edu/) and the Desktop Genetics tool
(https://www.deskgen.com/landing), we selected a pair of two guide RNA (gRNAs)
sequences of 20 base pairs each, targeting exon 3 of the human NQO1 gene
(ENSG00000181019) with an offset distance of 9 base pairs. The gRNA sequences
used were the following: NQO1-guideA (Sense): 5′-TAAGCCAGAACA-
GACTCGGC-3′ and NQO1-guideB (Antisense): 5′-CCATCTGAGCCCAGA-
TATTG-3′. The gRNA oligonucleotides were annealed and cloned into the
pSpCas9n(BB)-2A-Puro (PX462) V2.0 vector (Addgene plasmid # 62987), fol-
lowing the recommended protocol35.
Plasmid transfection: pSpCas9n(BB)-2A-Puro-NQO1-guideA and -guideB
constructs were co-transfected into HAP1 cells using Xfect transfection reagent
(Takara Bio USA, Inc.). After 2 days of selection with puromycin, loss of protein
expression was tested by immunoblotting.
CRISPR-Cas9-mediated editing: ΔLMNA and HAP1 cells were purchased from
Horizon Genomics. CRISPR-Cas9 knock-outs of FANCC, FANCI and BLM were
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generated in collaboration with Horizon Genomics. CRISPR-Cas9 knock-outs of
RMI1, FANCM, FANCC/BLM, FANCC/RMI1, FANCI/RMI1, and FANCD2/BLM
were generated using the protocol of Horizon Genomics. Sequences for gRNAs
were designed by Horizon Genomics or with the use of http://crispr.mit.edu/ and
https://www.deskgen.com/landing/, respectively. Sequences of gRNAs used were:
FANCC: 5′-GCCAACAGTTGACCAATTGT-3′;
FANCI: 5′-GTATCCAGTTGGTGGAATCG-3′;
FANCM(1): 5′-AAAGACCTTTATTGCCGCCG-3′;
FANCM(2): 5′-GGTCTACACAAGCTTCCACC-3′;
BLM: 5′-AGATTTCTTGCAGACTCCGA-3′;
RMI1: 5′-ATGTTAAAGTACCTCCGATG-3′;
P53: 5′-TCCTCAGCATCTTATCCGAG-3′;
Sanger sequencing. Genomic DNA was extracted using the Viagen Biotech
DirectPCR Lysis Reagent (Cell) according to the manufacture’s protocol. Genomic
regions around the gRNA-targeted sequences were ampliﬁed using the following
primer pairs:
FANCC-For: 5′-CAAACCTACACACACATACATGGAC-3′;
FANCC-Rev: 5′-ACTAAACAAGAAGCATTCACGTTCC-3′;
FANCI-For: 5′-CTTTTTCAAAGCCCTTAACCATTGC-3′;
FANCI-Rev: 5′-CCCTCAACAAATTACAAACCCTCAA-3′;
FANCM(1)-For: 5′-CGGACGATGATGTGTTGCTT-3′;
FANCM(1)-Rev: 5′-CGATCTGCTGTGTCACCAAG-3′;
FANCM(2)-For: 5′-AGTCCTAGATAAGTGCCAGCT-3′;
FANCM(2)-Rev: 5′-TATTTCAGCAGCGGGACAAG-3′;
BLM-For: 5′-GAGCAGTGCTTACTCTTACAAAGTG-3′;
BLM-Rev: 5′-GTTACCGAAGACTTTTCCTTCAGTG-3′;
RMI1-For: 5′-AAAAATCTAAAGGGTGTGCCTGTC-3′;
RMI1-Rev: 5′-TGCCATCGGGTAAAAGAGGATG-3′;
P53-For: 5′-TTATAGGGAGGTCAAATAAGCAGCA-3′;
P53-Rev: 5′-ATCTACAAGCAGTCACAGCACAT-3′;
The following sequencing primers were used:
FANCC: 5′-ACTAAACAAGAAGCATTCACGTTCC-3′;
FANCI: 5′-CTTTTTCAAAGCCCTTAACCATTGC-3′;
FANCM(1): 5′-CGATCTGCTGTGTCACCAAG-3′;
FANCM(2): 5′-TATTTCAGCAGCGGGACAAG-3′;
BLM 5′-GTTACCGAAGACTTTTCCTTCAGTG-3′;
RMI1 5′-TGCCATCGGGTAAAAGAGGATG-3′;
P53: 5′-TTATAGGGAGGTCAAATAAGCAGCA-3′;
PCR ampliﬁcation conditions: heat lid 110 °C; 94 °C 2 min; loop 35× (94 °C
30 s; 55 °C 30 s; 68 °C 1min) 68 °C 7 min. Frameshift mutations were identiﬁed
using Nucleotide BLAST against the reference genome GCF_000001405.33.
BRCA1 and MUS81 knock-down by shRNA. BRCA1 knock-down: The shRNA
constructs for BRCA1 were kindly provided by Sebastian M. Nijman (Ludwig
Institute for Cancer Research Ltd, UK). HAP1 cells were infected with the virus-
containing supernatant in the presence of polybrene (ﬁnal concentration 8 μg/ml),
in IMDM (10% FBS, 1% P/S), with a viral supernatant to medium ratio of 1:3.
Infected cells were selected using puromycin (2 μg/ml; Sigma-Aldrich) for 48 h.
MUS81 knock-down: Targeting sequences for MUS81 were selected using the
Broad Institute Genetic Perturbation Platform. Sense targeting sequences:
shMUS81#1: 5′-ACACTGCTGAGCACCATTAAG-3′; shMUS81#2: 5′-
CACGCGCTTCGTATTTCAGAA-3′. Oligos were cloned into the
“pLKO.2 stuffer” vector, provided by Sebastian M. Nijman. Virus was produced
using the pCMV-VSV-G envelope plasmid (Addgene # 8454) and the psPAX2
packaging plasmid (Addene # 12260) in HEK293 cells. For infection, 150 ul viral
supernatant was added to HAP1 cells 1 ml IMDM, following the Lipofectamine®
2000 Transfection protocol.
Quantitative reverse transcription PCR (RT-PCR). Cells were collected and
RNA was isolated using Trizol extraction (following manufactures instructions).
RNA was treated with 1 μl DNase (Sigma) and then reverse transcribed with the
SuperScript III Reverse Transcriptase protocol (Invitrogen) to obtain cDNA. An
amount of 1 μg of cDNA template was used for the qRT-PCR using SYBR Green
qPCR Mastermix (Qiagen). Analysis was performed in biological triplicates using
expression of GAPDH for normalization of data. The PCR was performed on a
7900HT Fast Real-Time PCR System (Applied Biosystems). The following primers
were used:
BRCA1: 5′-TCAACTCCAGACAGATGGGAC-3′; 5′-GGCTGTGGGGTTTCT
CAGAT-3′,
GAPDH: 5′-CGAGCCACATCGCTCAGACA-3′; 5′-GGCGCCCAATACGAC
CAAAT-3′.
Dose-response curves. Dose–response curves for MMC (Sigma-Aldrich), cis-
platin (Sigma-Aldrich), Acetaldehyde (Sigma-Aldrich), Diepoxybutane (Sigma-
Aldrich) and Nutlin-3a (Sigma-Aldrich) were performed as biolgical triplicates in
96-well plates by seeding 1000 cells per well, the day before treatment. The fol-
lowing day, drugs were added at 2-fold serial dilutions. Four days after the
initiation of the treatment, cell viability was measured using CellTiter-Glo
(Promega).
Colony formation assays. Cells were seeded in 6-well plates the day before the
treatment (1000 cells per well). The next day MMC or Nutlin-3a were added at the
indicated concentrations. Three days after the initiation of the treatment, drug-
containing medium was changed with fresh drug-free medium. Cells were left in
culture until visible colonies appeared (7–10 days). Colonies were then ﬁxed in
3.7% formaldehyde in phosphate-buffered saline (PBS) for 1 h, washed in PBS and
stained with 0.1% crystal violet solution in PBS supplemented with 10% ethanol for
1 h, followed by washing twice with H2O. For quantiﬁcation, crystal violet was
extracted using 50% EtOH and absorbance was measured at 595 nm.
Remodelin incubation and microscopy. Cells were adhered onto coverslips and
incubated with Remodelin at 1 μM for 2 days. To visualize nuclei, cells were
subsequently ﬁxed with 4% paraformaldehyde in PBS and stained with 4′,6-dia-
midino-2-phenylindole (DAPI). Images of cells were acquired using a Deconvo-
lution microscope (Leica). CellProﬁler software was used to quantify nuclear
circularity and nuclear area from DAPI staining pictures, using the ‘object size
shape’ measurement.
γH2AX staining and analysis. Cells were seeded in three 96-well plates (black
with clear ﬂat bottom tissue culture treated imaging microplates from Falcon) and
left to adhere over-night. Cells were either treated with 60 nM MMC or left
untreated. The experiments were done in triplicate wells. After 24, 48, and 72 h of
treatment, cells were ﬁxed with 100% methanol. Staining: Cells were blocked for 1 h
with Blocking Buffer (10% FCS and 0.1% Triton X-100 in PBS), incubated for 1 h
with the primary antibody (Anti-phospho-Histone H2A.X Ser139, clone JBW301
from Millipore/Upstate) at a dilution of 1:1000 in Blocking Buffer, washed three
times with PBS, incubated for 1 h with secondary antibody (Alexa Fluor 488 goat
anti-mouse IgG, H+L, from Invitrogen) diluted at 1:600 along with DAPI (0.2 mg/
ml stock from Sigma-Aldrich), diluted at 1:1000 in Blocking Buffer, washed 3 times
and left in PBS. Cells were imaged on the Operetta-High Content Imaging System
(Perkin Elmer, ×20 objective). The image analysis software Cell Proﬁler was used to
quantify the integrated intensity of nuclear γH2AX. Apoptotic cells were excluded
from the analysis. For each condition at least 1000 cells were quantiﬁed, except for
ΔFANCC time point 2 and 3 where 877 and 426 cells (respectively) were obtained.
R was used for data processing and normalization. The threshold between γH2AX
positive (integrated intensity > 10) and negative cells was determined by com-
paring treated and untreated cells.
Measurement of apoptosis. Cells were seeded as triplicates on day 1 in 10 cm
dishes and treated with 46 nM MMC on day 2, day 3, and day 4. On day 5, cells
were stained using the PE Annexin V Apoptosis Detection Kit I from BD Bios-
ciences according to the provided protocol and analyzed by ﬂow cytometry.
Metaphase spreads. Cells were seeded in 10 cm dishes and treated with MMC for
the indicated times. Colcemid (KaryoMAXTM, Gibco, Thermo Fisher Scientiﬁc)
was added at a ﬁnal concentration of 500 ng/ml 3 h before harvesting. Cells were
trypsinized and incubated in KCl 0.075 M (KaryoMAXTM, Gibco, Thermo Fisher
Scientiﬁc) for 6 min. After centrifugation, cells were resuspended in ﬁxation
solution (methanol:acetic acid 3:1) and incubated for 15 min at room temperature.
Centrifugation and re-suspension in fresh ﬁxation solution was repeated two times.
Metaphase spreads, slide preparation and measurement of chromosomal aberra-
tions was performed at Karyologic Inc (North Carolina, USA).
Immunoblotting and antibodies. Cell extracts were prepared in RIPA lysis buffer
(NEB) supplemented with protease inhibitors (Sigma) and phosphatase inhibitors
(Sigma, NEB). Immunoblots were performed using standard procedures. Protein
samples were separated by SDS–PAGE (4–12% gradient gels; Invitrogen) and
subsequently transferred onto nitrocellulose membranes. All primary antibodies
were used at 1:1000 dilution with the exception of BLM (1:500) and RMI1 (1:5000).
Secondary antibodies were used at 1:5000. The following antibodies were used:
FANCC clone 8F3 (Merck Millipore), FANCD2 EPR2302 (Abcam), FANCI A301-
254 (Bethyl laboratories), NQO1 clone A180 (Cell Signaling), RMI1 (Proteintech),
BLM clone C-18 (Santa Cruz), MUS81 clone MTA30 2G10/3 (Abcam), p21 clone
F-5 (Santa Cruz), β-Actin clone 20–33 (Sigma), Tubulin clone DM1A (Cell Sig-
naling), HRP-conjugated goat anti-mouse, rabbit or goat IgG (Jackson Immuno-
chemicals). The p53 antibody (PAB 421) was from Cancer Research UK.
Uncropped immunoblot images are shown in Supplementary Fig. 7.
Genome-wide CRISPR-Cas9 screen. GeCKO CRIPSR library virus was produced
as reported10 and described brieﬂy following, using both CRISPR library A and
library B in one production step: HEK-293T cells were seeded at 40% conﬂuency in
T-225 ﬂasks and 24 h later were transfected with GeCKO CRISPR library A and B,
pVSVg and psPAX2 plasmids using Lipofectamine® 2000 transfection reagent
(Invitrogen, ThermoFisher Scientiﬁc) according to the manufacturer's protocol.
After 6 h, the medium was changed with DMEM (10% FBS) and after 60 h, virus-
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containing supernatant was centrifuged at 700 × g at 4°C for 10 min and then
ﬁltered through a 0.45 μM ﬁlter (Millipore Steriﬂip HV/PVDF). Cells were infected
with a multiplicity of infection (MOI) between 0.3 and 0.5. For each screened cell
line, 100 million HAP1 cells were spinfected by centrifugation. Day 1: 12 6-well
plates were seeded with 1.5 million cells per well, supplemented with viral super-
natant and IMDM (10% FBS, 1% P/S) to reach a volume of 1 ml per well. Polybrene
was added at 8 μg/ml. Cells were spinfected for 3 h at 724×g at 37 °C, pooled and
transferred into 15 cm dishes. Day 3: Cells were challenged with 2 μg/ml puromycin
to deplete uninfected cells. Day 5: WT cells were challenged with 30ml of 190 nM
mitomycin C (MMC) in IMDM (10% FBS, 1% P/S) per 15 cm dish. ΔFANCC cells
were challenged with 30ml of 46 nM MMC in IMDM (10% FBS, 1% P/S) per 15 cm
dish. Treated cells were incubated for 10 days following MMC challenge, WT
untreated cells were split every 2–3 days for 10 days to avoid conﬂuency, re-seeding
> 100 million cells each time. Genomic DNA of at least 30 million cells per sample
was extracted using the Qiagen Blood & Cell Culture DNA Maxi Kit according to
the manufacture’s protocol. PCR was performed in two steps, using PCR1- and
barcoded PCR2 primers as reported10, obtained from http://genome-engineering.
org/gecko/wp-content/uploads/2013/12/GeCKO-plasmid-readout-primers-
July2014.xlsx. PCR1 ampliﬁed the gRNA sequences of 130 μg genomic DNA in
13 × 100 μl reactions per sample using the Promega GoTaq® G2 DNA Polymerase.
PCR1 reaction tubes were pooled for each sample. PCR2 added Illumina sequencing
adapters by performing 16 × 100 μl PCR reactions per sample with 2 μl input DNA
from PCR1 per reaction tube. PCR program for PCR1 and PCR2: Heat lid 110 °C;
94 °C 2min; loop 18× (94 °C 30 s; 55 °C 30 s; 68 °C 1min) 68 °C 7min. PCR2
products were puriﬁed by running them on agarose gel and DNA was extracted
using the Promega Wizard® SV Gel and PCR Clean-Up System. Barcoded samples
were pooled and submitted to the Biomedical Sequencing Facility (BSF) for 61 base
pair single-end sequencing. Barcoded samples from the CRIPSR library screen were
de-multiplexed by the BSF. Enrichment analysis for gRNAs was performed using
the MAGeCK-VISPR analysis and visualization software36 by comparing the MMC
treated ΔFANCC sample to WT untreated, or WT MMC treated to WT untreated
respectively (positive selection).
Genome-wide insertional mutagenesis screen. For gene-trap insertional muta-
genesis we followed the published protocol5 as described brieﬂy following: Gene-
trap virus was produced in HEK293T, that were seeded in 15 cm dishes and
transfected with the gene-trap plasmid and packaging plasmids VSVg, gag-pol and
pAdVAntage™ Vector (Promega) using Lipofectamine® 2000 Transfection reagent
(Invitrogen, ThermoFisher Scientiﬁc) according to manufecturer’s protocol. The
following day, medium was replaced with fresh DMEM (20% FBS, 1% Pen/strep).
Retroviral supernatant was collected for three consecutive days, centrifuged at
700 × g for 10 min, ﬁltered through a 0.45 μM ﬁlter (Millipore Steriﬂip HV/PVDF)
and ultracentrifuged at 70,737 × g (average RCF) at 4 °C for 90 min with a SW 32Ti
rotor (Beckman Coulter). Viral pellets were re-suspended in PBS, pooled and
ΔFANCC HAP1 cells were transduced with concentrated retrovirus containing the
gene-trap cassette5. After integration of the GFP-expressing gene-trap cassette, cells
were analyzed by ﬂow cytometry to measure efﬁciency of infection and populations
with> 70% GFP-expressing cells were used for treatment with MMC. The control
non-selected WT HAP1 data-set was taken from Blomen et al.8. 100 million cells
from the mutagenized pools were seeded in 15 cm dishes at a density of 6 million
cells per dish. The following day MMC was added at a concentration that selec-
tively killed FANCC-deﬁcient cells, leaving only around 5–10% of cells surviving
(46 nM for FANCC). Cells were left to grow for 10 days. After the end of treatment
cells were trypsinized and frozen at −80 °C. For preparation of the gene-trapped
DNA libraries, genomic DNA was extracted from 30 million cells using QIAamp
DNA mini kit (Qiagen), subjected to digestion with MseI (NEB) and NlaIII
enzymes (NEB) and subsequently ligated by T4 DNA ligase (NEB). Digested and
ligated fragments were used as template for inverse PCR with primers targeting the
LTR regions of the gene-trap cassette. After ampliﬁcation and puriﬁcation of the
fragments the DNA sample was submitted for next generation sequencing (Illu-
mina HiSeq 2000, 50 base pair single-read) to the CeMM Biomedical Sequencing
Facility (BSF). Bioinformatics analysis of the next generation sequencing data was
done in R according to Carette et al.5 as follows: Brieﬂy, raw sequencing data was
aligned to human reference genome hg19 (UCSC hg19 build) using bowtie2
(version 2.2.4) with default parameter. Reads were removed that did not meet the
following criteria: (1) have a reported alignment-“mapped reads” (2) have a unique
alignment (3) have a mapping quality (MAPQ) higher than 20. Duplicate reads
were marked and discarded with Picard (version 1.111). Insertions in close
proximity (1 or 2 base pairs distance from each other) were removed to avoid
inclusion of insertions due to mapping errors. Insertions were annotated with gene
build GRCh37.p13 (ENSEMBL 75-release February 2014) using bedtools (version
2.10.1) and custom scripts. The canonical transcripts (according to ENSEMBL) for
each gene were used as a reference gene model to count insertions falling with
exons, introns or intragenic. Insertions were considered mutagenic or disruptive to
the gene if they occurred within exons irrespective of their orientation to the
corresponding gene or if they were located within introns in sense orientation.
Insertions in antisense direction in respect to the gene orientation were considered
silent. All mutagenic insertions were summarized independently for each gene. For
each gene a one-sided Fisher’s exact-test was applied to estimate a signiﬁcant
enrichment of insertions over an unselected control data set.
Statistical analysis. For gene-trap and CRISPR library screens, hit selection was
performed in two steps. First, each data set was partitioned into two groups,
deﬁning the hit-group as data points with p < 0.001 and fold-change> 21.5. In the
second step, hit selection was optimized using linear discriminant function ana-
lysis. Dose-points of survival curves indicate the mean of biological triplicates, with
S.E.M. shown as error bars. The p-values for the γH2AX staining were determined
by two-way ANOVA. Means and S.E.M. of biological triplicates are plotted. The p-
values for the chromosomal breaks and gaps/metaphase were determined by
Mann–Whitney U test. Means and S.E.M. of biological triplicates are plotted.
Data Availability. All data generated or analyzed during this study is included in
this published article and its Supplementary Information.
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